NCT04774952 2025-04-15Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Completed58 enrolled
NCT02164461 2024-05-20Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical CancerAdvaxis, Inc.Phase 1 Completed12 enrolled 18 charts
NCT03989115 2023-06-26Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCRevolution Medicines, Inc.Phase 1/2 Completed113 enrolled 22 charts
NCT01234480 2023-05-16Intended Use Study of the BD SurePath Plusâ„¢ PapBecton, Dickinson and CompanyTerminated5,859 enrolled 4 charts
NCT03634982 2022-09-01Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsRevolution Medicines, Inc.Phase 1 Unknown133 enrolled
NCT03544723 2020-06-09Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.MultiVir, Inc.Phase 2 Unknown40 enrolled